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A bromodomain–DNA interaction facilitates
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Bromodomains are critical components of many chromatin modifying/remodelling proteins
and are emerging therapeutic targets, yet how they interact with nucleosomes, rather than
acetylated peptides, remains unclear. Using BRDT as a model, we characterized how the BET
family of bromodomains interacts with site-speciﬁcally acetylated nucleosomes. Here we
report that BRDT interacts with nucleosomes through its ﬁrst (BD1), but not second (BD2)
bromodomain, and that acetylated histone recognition by BD1 is complemented by a
bromodomain–DNA interaction. Simultaneous DNA and histone recognition enhances
BRDT’s nucleosome binding afﬁnity and speciﬁcity, and its ability to localize to acetylated
chromatin in cells. Conservation of DNA binding in bromodomains of BRD2, BRD3 and BRD4,
indicates that bivalent nucleosome recognition is a key feature of these bromodomains and
possibly others. Our results elucidate the molecular mechanism of BRDT association with
nucleosomes and identify structural features of the BET bromodomains that may be targeted
for therapeutic inhibition.
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T
he basic repeating unit of chromatin is the nucleosome,
consisting of two copies each of four core histones
(H2A, H2B, H3 and H4) wrapped in B147 bp of DNA1.
This repeating unit, and the higher order structures it forms,
serves to regulate DNA accessibility for tight control of all DNA-
templated processes. Access is mediated by epigenetic modi-
ﬁcations including histone posttranslational modiﬁcations and
DNA methylation, which either directly inﬂuence chromatin
structure, or recruit or repel chromatin effector proteins that
harbour modiﬁcation-speciﬁc DNA or histone-binding modules,
such as bromodomains2–4.
The bromodomain and extra-terminal (BET) family (BRD2, 3,
4 and BRDT in human) are multi-functional chromatin effector
proteins, whose critical roles in transcription and chromatin
biology have made them attractive therapeutic targets for a wide
range of malignancies (recently reviewed in refs 5–7). These
proteins have a domain architecture that is conserved from
yeast to human, which features two N-terminal bromodomains
separated by a linker of B110 amino acids, a ‘motif B’ that
mediates BET protein dimerization8, and a characteristic extra-
terminal domain that acts as a protein–protein interaction
module for recruiting cofactors involved in transcriptional
regulation9,10. Additionally, longer isoforms of BRD4 and
BRDT (Fig. 1a) have an extended C-terminus that allows them
to facilitate RNA polymerase II-dependent transcription through
interactions with the positive-transcriptional elongator
complex11,12.
Bromodomains recognize acetylated lysine residues and have
a highly conserved structural fold consisting of four a-helices
(aZ, aA, aB, aC) forming a compact left-handed bundle. Variable
loops connecting helices aZ–aA (ZA loop) and aB–aC (BC loop)
shape the acetyl–lysine binding pocket, thus contributing to
substrate speciﬁcity13,14. Structure-based alignments and
phylogenetic analysis of the 61 human bromodomains, which
are found in 46 diverse proteins, divides them into eight distinct
families14. The variability of the acetylated lysine pockets has
recently allowed the development of inhibitors that are speciﬁc
against various members of these families, particularly the BETs
(recently reviewed in ref. 15).
Bromodomains typically bind to acetylated lysine residues with
relatively low afﬁnity (micromolar) and relatively poor selectivity
for single acetylated-lysine residues within an isolated peptide14.
However, speciﬁcity and afﬁnity are frequently increased in the
presence of multiple modiﬁcations. For example, both
bromodomains of BRDT, the testis-speciﬁc member of the BET
family that is essential for spermatogenesis, show a preference for
multiply acetylated histone peptides16,17. The ﬁrst bromodomain
of BRDT (BD1) preferentially binds histone H4 tail peptides
acetylated at lysines 5 and 8 (H4K5acK8ac), while the second
bromodomain (BD2) has highest afﬁnity for histone H3 tail
peptides acetylated at lysines 18 and 23 (H3K18acK23ac). In both
cases, binding to individually acetylated peptides is either weaker
or could not be determined16. Notably, the crystal structure of the
BD1-H4K5acK8ac peptide complex revealed that the single
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Figure 1 | The nucleosome structure augments acetylated histone tail binding by BRDT-BD1 but prevents interaction with BRDT-BD2. (a) Domain
layout of human BRDT. (b) ITC proﬁles for N-BRDT(1) interactions with either acetylated histone H4 tail peptides or acetylated nucleosomes
(both H4K5acK8ac), as indicated. (c) ITC proﬁles for BRDT(2) interactions with either acetylated histone H3 tail peptides or acetylated nucleosomes
(both H3K18acK23ac), as indicated.
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binding pocket of BD1 can simultaneously bind to both
acetylated lysines of a K5acK8ac peptide16.
There is increasing recognition that multivalency is a central
component of chromatin biology. Chromatin-binding proteins
and complexes frequently use multiple low-afﬁnity interactions
to achieve afﬁnities, speciﬁcities and dynamics that would
otherwise be impossible through monovalent interactions18.
These multivalent interactions can occur either through the
combination of histone or DNA interactions within a single
protein, or within a complex carrying several chromatin-binding
domains (recently reviewed in refs 19,20). Typically these
interactions have been studied using a ‘divide and conquer’
approach, particularly in studies of histone tail binding by
chromatin readers that have predominantly used isolated histone
peptides in place of nucleosomes.
To gain a more comprehensive picture of how BET
bromodomains interact with chromatin, we sought to character-
ize how BRDT, with its tandem bromodomains, interacts with
acetylated nucleosomes. Using a combination of biophysical
methods, including isothermal titration calorimetry (ITC) and
methyl-TROSY NMR, we ﬁnd that BRDT interacts with
acetylated nucleosomes through BD1 only, while BD2 is
unexpectedly unable to interact with acetylated histones within
a nucleosome. We show that BRDT-BD1 binding to nucleosomes
is bivalent and consists of simultaneous recognition of both
acetylated histone tails and DNA. Importantly, we ﬁnd that the
bromodomain–DNA interaction is nonspeciﬁc and facilitates
recruitment of BRDT to bulk chromatin, where it may assist
BRDT in bringing about chromatin compaction in response to
histone hyperacetylation in cells. We ﬁnd similar DNA binding in
other members of the BET bromodomain family, suggesting that
this bivalent mode of recruitment is not limited to BRDT. Our
results offer an in-depth characterization of bromodomain
association with acetylated nucleosomes and highlight the
importance of nucleosome components beyond the histone tail
for bromodomain recognition.
Results
Nucleosome structure inﬂuences bromodomain binding. The
interactions of the BET bromodomains with chromatin have
largely been studied by two approaches. First, chromatin immu-
noprecipitation experiments and pull-downs have been used to
correlate BET binding with the presence of particular histone
modiﬁcations on chromatin in vivo14,21. Alternatively, the
bromodomains have been tested individually by in vitro
experiments, such as peptide arrays and ITC, to investigate
their binding preferences for speciﬁcally modiﬁed histone tail
peptides14,16. Here we extend these studies and use BRDT to
characterize the interaction of the BET bromodomains with
in vitro reconstituted, site-speciﬁcally acetylated nucleosomes.
On the basis of previous characterization of the binding
speciﬁcities of the two bromodomains of murine Brdt16, we
utilized a histone semisynthesis approach and native chemical
ligation to reconstitute four types of acetylated nucleosomes
in vitro22,23. These nucleosomes were either unmodiﬁed,
acetylated on histone H4 (H4K5acK8ac), acetylated on histone
H3 (H3K18acK23ac) or acetylated on both H3 and H4. The
histone modiﬁcations did not interfere with octamer or nucleo-
some refolding (Supplementary Fig. 1) and therefore were used to
investigate how nucleosome structure affects bromodomain
binding to histone tails.
We tested two BRDT bromodomain constructs for their
histone- and nucleosome-binding properties. The ﬁrst construct
(N-BRDT(1), residues 1–143) included the core bromodomain
fold of BD1 and the N-terminus of BRDT that has been shown to
be essential for BRDT’s ability to compact acetylated chromatin24.
The second construct, (BRDT(2), residues 258–383) was based on
the murine Brdt-BD2 bromodomain crystal structure16.
As expected, ITC showed that N-BRDT(1) requires acety-
lation of histone H4 for binding to histone peptides and
nucleosomes. No binding was detected for unmodiﬁed samples
(Supplementary Fig. 2a,b), whereas the dissociation constants
between N-BRDT(1) and H4K5acK8ac acetylated peptides and
nucleosomes were found to be 13 mM and 2 mM, respectively,
(Fig. 1b). These data show that BRDT-BD1 interacts with
nucleosomes with a 46-fold enhancement in afﬁnity compared
with acetylated H4 histone tail peptides alone, and indicates that
the nucleosome structure is an important determinant of histone
tail recognition.
Surprisingly, our ITC data indicated that BRDT(2) cannot
interact with acetylated nucleosomes, despite interacting with the
equivalently acetylated histone H3 peptides (Fig. 1c). This
suggests that the nucleosome structure prevents BRDT(2) from
binding the H3 tail.
To conﬁrm our ITC data and further characterize how BRDT
interacts with nucleosomes, we adopted the methyl-TROSY
NMR methodology that facilitates the investigation of large
complexes25. Here 13C, 1H methyl groups of isoleucine, leucine
and valine in a perdeuterated background were used as sensitive
probes for monitoring interactions between the bromodomains
and acetylated nucleosomes.
Consistent with our ITC data, N-BRDT(1) interacted with
(H4K5acK8ac) acetylated nucleosomes (Fig. 2a), whereas BRDT(2)
showed no interaction with H3K18acK23ac acetylated nucleo-
somes (Supplementary Fig. 2c). For N-BRDT(1), overlaid 13C-1H
methyl-TROSY spectra showed chemical shift perturbations
(CSPs) in residues surrounding the acetylated lysine-binding
pocket when tested with both (H4K5acK8ac) acetylated peptides
and nucleosomes (Fig. 2a,b). In addition, binding of N-BRDT(1)
to acetylated nucleosomes also induced speciﬁc CSPs distinct
from those caused by peptide binding alone (Fig. 2a,b). These
perturbations occurred towards the opposite end of N-BRDT(1)
(relative to the histone-binding pocket), and suggest that BD1
may make additional contacts with the nucleosome outside of the
histone H4 tail.
BRDT-BD2 is tethered to acetylated nucleosomes by BD1. We
hypothesized that BRDT-BD2 may require BRDT-BD1 for
recruitment to acetylated nucleosomes and thus may only bind
when tethered by BD1. Therefore, we expressed and puriﬁed a
longer BRDT construct encompassing both bromodomains
(BRDT(1-2)) to verify whether both BD1 and BD2 interact with
acetylated nucleosomes when linked.
We ﬁrst characterized this construct by size-exclusion
chromatography, analytical ultracentrifugation, NMR spectro-
scopy and small angle X-ray scattering (SAXS) (Supplementary
Fig. 3) and found that BRDT(1–2) is a monomeric, elongated and
ﬂexible molecule with the two bromodomains at either end of an
unfolded linker (Supplementary Fig. 3). Comparison of overlaid
1H, 15N HSQC spectra (Supplementary Fig. 3c) and 13C-1H
methyl-TROSY spectra (Supplementary Fig. 4a) of BRDT(1–2)
with individual N-BRDT(1) and BRDT(2) data showed a good
correspondence between peak positions. Our experimental data
therefore give no indication of signiﬁcant changes in the folds of
these domains when linked, nor of dimerization between them, as
has been proposed for other bromodomains of the BET
family8,26,27. New resonances, which appeared in the BRDT
(1–2) 1H, 15N HSQC spectrum (Supplementary Fig. 3c), were
attributed to the linker; these resonances were predominantly
grouped in the middle of the spectrum and have signiﬁcantly
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higher intensities, suggesting that the linker is unstructured.
Comparable peak intensities for the resonances of the bromo-
domains in the linked construct, when compared with those of
N-BRDT(1) and BRDT(2) alone, indicate that the two domains
rotate independently of each other.
We then tested how BRDT(1–2) interacts with acetylated
peptides and nucleosomes using leucine and valine 13C-1H
methyl-TROSY NMR. Overlaid spectra of samples containing
BRDT(1–2) and acetylated H3 or H4 histone peptides show CSPs
for both BD1 and BD2 (Supplementary Fig. 4a, lower panels).
The observed CSPs occur in almost identical resonances regar-
dless of the peptide, as would be expected for both peptides targ-
eting the histone-binding pockets. These data therefore show that
both bromodomains bind to both acetylated histone peptides and
highlight the lack of speciﬁcity of individual bromodomains for
acetylated histone peptides alone.
In contrast to the peptide binding, we found that only BD1 was
able to interact with nucleosomes uniformly acetylated on both
histones H3 (K18acK23ac) and H4 (K5acK8ac) (Supplementary
Fig. 4b, lower panels). Resonances from the linker and BD2 did
not show evidence of interaction with the nucleosomes and
appear to have remained ﬂexible in solution. This result shows
that tethering of the BD2 to nucleosomes is not sufﬁcient to
induce interaction.
To conﬁrm that the experimental conditions were conducive to
seeing binding between BD2 and nucleosomes, we repeated the
experiments with acetylated histones from the puriﬁed octamer
used for nucleosome reconstitution. BRDT(1–2) binding was
tested under the same concentrations and buffer conditions as the
nucleosome experiments (Supplementary Fig. 4b, upper panels).
Here BD2 interacted with the histones, demonstrating that BD2 is
unable to bind to acetylated H3 tails when presented in the
context of a nucleosome.
BRDT interacts non-speciﬁcally with DNA through BD1.
Given the proximity of the histone H4 tail to the DNA that
encircles the histone octamer, we investigated whether BRDT-
BD1 might interact with DNA using electrophoretic mobility shift
assays (EMSAs). Strikingly, N-BRDT(1) showed robust binding
to the 167 bp Widom DNA that we use for reconstituting
nucleosomes (15 mM) (Fig. 3a), whereas BRDT(2) did not interact
with the DNA (Supplementary Fig. 5).
To investigate the binding speciﬁcity and stoichiometry of
these interactions, we tested N-BRDT(1) binding to 66 and 25 bp
DNA oligonucleotides (Fig. 3b). These oligonucleotides had an
unrelated sequence to the previously tested 167 bp DNA
(sequences in Methods). N-BRDT(1) interacted with each of
the DNAs, showing that it interacts with nucleic acids without
sequence speciﬁcity. Quantiﬁcation of the EMSAs showed that
N-BRDT(1) interacts with 66 and 25 bp DNAs with dissociation
constants of 29mM and 52 mM, respectively. An apparent increase
in afﬁnity as the DNA length increases is expected for a non-
speciﬁc DNA-binding protein presented with an increased
number of potential binding sites in longer DNA. Accordingly,
the shifts seen in the EMSAs suggest that at least two N-BRDT(1)
molecules can interact with 66 bp DNA, whereas only a single
shift is seen for 25 bp DNA (Fig. 3b, arrowheads).
Our ITC data (Fig. 1b; Supplementary Fig. 2a,b) suggested that
N-BRDT(1) required acetylation of H4 to bind to nucleosomes,
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however, binding of N-BRDT(1) to free DNA would suggest that
it should also bind non-speciﬁcally to nucleosomes, independent
of acetylation. To test this, we performed EMSA experiments with
167 bp Widom DNA and unmodiﬁed or acetylated nucleosomes
(Fig. 3c). We found that N-BRDT(1) did indeed show weak
binding to unmodiﬁed nucleosomes in a similar manner seen for
DNA. The apparent discrepancy with the ITC result suggests
that—due to limitations in the achievable sample concentra-
tions—the interaction could not be detected under our experi-
mental conditions.
As predicted from our ITC experiments (Fig. 1b), N-BRDT(1)
binds with a signiﬁcantly higher afﬁnity and apparent
speciﬁcity to nucleosomes containing acetylated histone H4
(Fig. 3c). In contrast, BRDT(2) showed no interaction
with unmodiﬁed or acetylated nucleosomes (Supplementary
Fig. 5), supporting our ﬁndings from NMR and ITC
experiments.
These data demonstrate DNA binding by a bromodomain and
show that BRDT-BD1 interacts non-speciﬁcally with DNA and
nucleosomes. BRDT therefore has a signiﬁcantly different mode
of interacting with nucleosomes than previously envisaged, and
may target bulk chromatin through low afﬁnity, non-speciﬁc
DNA interactions, priming it to interact tightly and speciﬁcally
following histone hyperacetylation.
BD1 interacts with DNA and H4 through distinct interfaces.
To further characterize the BD1–DNA interaction, we analyzed
the sequences of human BRDT BD1 and BD2 (Supplementary
Fig. 6a), the X-ray crystal structure of BD1 (2RFJ14) and a
homology model of BD2 (generated using the Phyre2 web
server28) (Fig. 4a). These analyses identiﬁed a positively charged
patch in BD1 but not BD2 that correlates in location with
residues showing NMR CSPs speciﬁc to nucleosome binding
(Fig. 2a,b). We speculated that this region may be responsible for
interacting with DNA and may explain the difference in DNA
binding between BD1 and BD2.
The positively charged patch of BD1 is centered on the ﬁrst
a-helix (aZ) and features three prominent lysine residues
(K37, K41 and K45) (Fig. 4a). We mutated these three lysines
to serine both individually and in combination to test their effect
on DNA binding.
We recorded 1D NMR spectra to ensure that the mutations
had not affected the folding of the bromodomains and
additionally tested each of the mutated proteins by ITC for
binding to H4K5acK8ac peptides (Supplementary Fig. 6b,c).
Neither mutation of the central lysine, nor triple mutation
signiﬁcantly altered the 1D NMR spectra or the acetylated histone
H4 peptide-binding afﬁnity in ITC. This is in contrast to a
previously characterized point mutation in the histone-binding
pocket (I155Y) that, despite maintaining the bromodomain fold,
signiﬁcantly reduced the binding afﬁnity of N-BRDT(1) for
acetylated histone peptides from 13 to4600 mM (Supplementary
Fig. 6b,c).
Interestingly, individual mutation of each lysine reduced
N-BRDT(1) binding to DNA, with the most pronounced effect
seen by mutating the central lysine (K41S) (Fig. 4b). Double
mutation of lysine residues 37 and 41 (2KS), or triple mutation of
all three (3KS) abolished DNA binding (Fig. 4b).
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The bromodomain is a small domain and given the spatial
proximity between the histone-binding pocket and DNA-binding
interface, we speculated that DNA binding may be inﬂuenced
by histone tail binding. We performed quantitative EMSA
titrations comparing N-BRDT(1) binding to 66 bp DNA þ /
H4K5acK8ac peptides. Peptide binding did not signiﬁcantly affect
N-BRDT(1)’s afﬁnity for 66 bp DNA (33 mM and 29 mM,
respectively; Supplementary Fig. 7), showing that the two binding
sites function independently. Therefore, the increased binding
afﬁnity between BRDT-BD1 and nucleosomes, when compared
with DNA or histone peptides alone, appears to occur largely
through the entropic beneﬁts of bivalency18, rather than through
allostery or the direct effect of a composite binding interface, such
as seen for the chromodomain of Chp1 (ref. 29).
Next, we tested the afﬁnity of our N-BRDT(1) DNA binding
mutants for H4K5acK8ac nucleosomes, to quantify the role of DNA
binding in nucleosome recognition (Fig. 4c). The single point
mutation of the central lysine (K41S) reduced nucleosome-binding
afﬁnityB3.5-fold (7mM), while triple mutation of all three lysines
further reduced the afﬁnity to 9mM; approaching the afﬁnity of
N-BRDT(1) for H4K5acK8ac peptides alone (B13mM) (Fig. 1b).
These results show that the BD1–DNA interaction contributes to
nucleosome-binding afﬁnity. BRDT-BD1 thus interacts bivalently
with nucleosomes via a combination of acetylation-speciﬁc histone
recognition and non-speciﬁc DNA binding.
Nucleosome structure inﬂuences bromodomain speciﬁcity. We
have demonstrated that BRDT-BD1 interacts with both acetylated
histone tails and DNA simultaneously to augment its nucleo-
some-binding afﬁnity; however, we also wanted to address the
issue of whether nucleosome structure contributes to binding
speciﬁcity. Bromodomains are promiscuous for binding to
acetylated lysine residues within a variety of sequence contexts14.
Although multiple acetylations within a single peptide enhance
both the speciﬁcity and afﬁnity of BET bromodomain binding,
some (particularly BRD4-BD2) are still able to bind to a large
variety of multiply acetylated histone peptides14.
To investigate whether nucleosome structure contributes to
target speciﬁcity, we produced chimeric nucleosomes in which
the acetylated histone H4 tail (H4K5acK8ac) was ligated to the
core of histone H3. This allowed us to test the binding afﬁnity of
N-BRDT(1) to nucleosomes containing the optimal acetylated
histone H4 recognition motif (H4K5acK8ac), but in an alternative
position on the nucleosome.
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Our ITC data indicate that N-BRDT(1) interacts with chimeric
nucleosomes with a dissociation constant of 5mM (Supplementary
Fig. 8). Notably, this represents an B2.5-fold enhancement in
binding afﬁnity over the interaction between N-BRDT(1) and the
H4K5acK8ac peptide, but an B2.5-fold decrease in afﬁnity
compared with H4K5acK8ac nucleosomes (Fig. 1b). We propose
that DNA binding localizes the bromodomain to the chimeric
nucleosome in the same manner as for the wild type (WT)
nucleosome, thus enhancing the local concentration and afﬁnity.
However, in the case of the WT nucleosome, the position of the
acetylated histone tail relative to the acetyl–lysine-binding pocket
(orientated by the DNA) is more favourable compared with the
same acetylated sequence in the chimeric location. Therefore, the
afﬁnity for the WT nucleosome is higher and an additional layer of
speciﬁcity is generated.
This result shows that the peptide sequence surrounding
acetylated lysines is not the only determinant of bromodomain
speciﬁcity. Rather, the nucleosome structure and, speciﬁcally, the
position of the acetylated lysines relative to DNA also inﬂuence
bromodomain recognition. This demonstrates that the speciﬁcity
of a chromatin reader can only accurately be evaluated with
nucleosomes and/or chromatin and cannot be reliably judged at
the level of peptides.
Other BET bromodomains interact with DNA. To investi-
gate whether DNA binding is a general feature of the BET
bromodomains or is speciﬁc to BRDT-BD1, we inspected the
electrostatic surface charges of the human BET bromodo-
mains and found that each member (with the exception of
BRDT-BD2) also contains a positively charged patch (Fig. 5a).
Although the residues involved are not identical to those in
BRDT-BD1, the positional conservation of this patch suggests
that this region may also interact with DNA. We therefore
tested the other bromodomains for DNA binding by
EMSA (Fig. 5b). Interestingly, the ﬁrst bromodomain of BRD2
and the second bromodomains of BRD2, 3 and 4 all interacted
with DNA, demonstrating that bromodomain-mediated DNA
binding is a conserved feature among all members of the BET
family.
Surprisingly, however, the ﬁrst bromodomains of BRD3 and
BRD4 did not interact with DNA, despite the presence of
the positively charged face. This result shows that inspection of
the electrostatic surface potentials alone is not adequate
for predicting an interaction between the bromodomains and
DNA. The positive charge of this surface is therefore necessary
but not sufﬁcient for DNA interaction and speciﬁc residues
and/or conformation must also be important.
a
c
0 1 2 3 4 5
–10.0
–8.0
–6.0
–4.0
–2.0
–0.30
–0.20
–0.10
0.00
0 10 20 30 40
Time (min)
Molar ratio
Kd = 12 μM
0 1 2 3 4 5
–8.0
–6.0
–4.0
–2.0
0.0
–0.30
–0.20
–0.10
0.00
0 10 20 30 40
Time (min)
μc
a
l s
–
1
Molar ratio
kc
al
 m
ol
–
1  
o
f i
nje
cta
nt
Kd = 13 μM
BRD4(1)
b
BR
D
2(1
)
BR
D
2(2
)
BR
D
3(1
)
BR
D
3(2
)
BR
D
4(1
)
BR
D
4(2
)
–
H4K5acK8ac
Nucleosome
H4K5acK8ac
Peptide
H4
5
8
H4
H4 5
8
5
8
–3
3
BD1 BD2
BRD4
BRDT
BRD2
BRD3
200
75
(bp)
300
500
1,500
Figure 5 | Other BET bromodomains interact with DNA. (a) Structures of the human BET bromodomains (PDB codes: BRDT-BD1 (2RFJ); BRD3-BD1
(2NXB); BRD3-BD2 (2OO1); BRD4-BD1 (2OSS, N-terminally truncated to R58 for comparison with other BD1 structures); BRD4-BD2 (2OUO)14; BRD2-BD1
(1X0J)26; BRDT-BD2 structure is a homology model generated using the Phyre2 web server28; BRD2-BD2 (2DVV)). Structures are shown as cartoons with
side chain sticks and partially transparent electrostatic surfaces generated using PBD2PQR and APBS56–58. (b) EMSA of BET bromodomains (as indicated)
interacting with 167 bp double stranded DNA. DNA (0.5mM) was mixed with BET bromodomains (100mM) in a ﬁnal volume of 4ml and incubated for
30min before native-PAGE electrophoresis at 4 C and visualization with ethidium bromide staining. (c) ITC proﬁles for BRD4(1) interactions with
H4K5acK8ac peptides and nucleosomes, as indicated.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13855 ARTICLE
NATURE COMMUNICATIONS | 7:13855 | DOI: 10.1038/ncomms13855 | www.nature.com/naturecommunications 7
Given the difference we ﬁnd in the DNA binding ability of
BRD4-BD1 and BRDT-BD1, we wondered if this was reﬂected in
their nucleosome-binding afﬁnities. We therefore compared
BRD4-BD1 binding to acetylated nucleosomes and histone
peptides by ITC (Fig. 5c). Interestingly, in contrast to BRDT-
BD1, BRD4-BD1 does not bind acetylated nucleosomes with
higher afﬁnity than acetylated histone peptides. This supports our
hypothesis that the BRDT-BD1–nucleosome interaction is
bivalent and is enhanced by simultaneous interaction with
acetylated histone H4 and DNA. BRD4-BD1 does not interact
with DNA, thus, the binding afﬁnities for histone peptides and
nucleosomes are the same.
BD1-DNA binding helps recruit BRDT to chromatin in cells.
Histone binding by BRDT-BD1 is essential for BRDT’s ability to
compact chromatin in an acetylation-dependent manner16,24.
To investigate whether BD1-mediated DNA binding has a similar
functional signiﬁcance, we assayed WT and mutant BRDT
constructs for their ability to localize to, and compact, hypera-
cetylated chromatin when ectopically expressed in cells. On the
basis of equivalent studies on murine Brdt16,24, we cloned a GFP-
tagged human BRDT construct (aas 1–444; DC-sBRDT) that is
predicted to be highly active in chromatin compaction. We then
made triple lysine to glutamate (3KE) mutations that abolished
N-BRDT(1) DNA binding (Fig. 6a), without interfering with
acetylated histone peptide recognition (Fig. 6b). ITC data indi-
cate that N-BRDT(1)-3KE has a ﬁvefold reduced afﬁnity for
H4K5acK8ac acetylated nucleosomes when compared with WT
N-BRDT(1) (Fig. 6b).
Fluorescence recovery after photobleaching (FRAP) experi-
ments show that WT human and murine DC-sBRDT constructs
have similar ﬂuorescence recovery half-lives (T1/2¼ 5–7 s)
following trichostatin A (TSA)-induced histone hyperacetylation
(Fig. 6c; Supplementary Fig. 9). This suggests that the human
protein interacts with acetylated chromatin in a similar manner to
the murine protein. In contrast, human and murine DC-sBRDT
proteins with mutations in their histone-binding pockets
(I115Y and P50A/F51A/V55A (PFV1)16,24, respectively), and a
DNA-binding deﬁcient human protein (DC-sBRDT-3KE)
showed a signiﬁcantly faster recovery half-life (T1/2¼B1.5 s);
indicative of reduced association with acetylated chromatin
(Fig. 6c; Supplementary Fig. 9). Double mutation of both the
histone and DNA-binding interfaces of human DC-sBRDT
(3KE/I115Y) did not further decrease the ﬂuorescence recovery
half-life. Mutation of either site alone is therefore sufﬁcient to
prevent acetylated chromatin association in cells (Fig. 6c;
Supplementary Fig. 9). Control FRAP experiments with and
without TSA conﬁrm that human DC-sBRDT 3KE, I115Y and
double mutants are similarly unresponsive to TSA-induced
histone hyperacetylation (Supplementary Fig. 10).
In accordance with the ﬁndings above, human DC-sBRDT-
3KE, I115Y and the double mutant are also compromised in their
ability to compact TSA-induced hyperacetylated chromatin in
cells, when compared with the WT protein (Fig. 6d). Instead,
DC-sBRDT with the 3KE and/or I115Y mutations remains diffuse
in the nucleus following TSA treatment. These results support our
ﬁnding that BRDT-BD2 cannot associate with nucleosomes;
showing that only a fully functional BD1, capable of bivalent
recognition of both DNA and acetylated histone tails, is able to
recruit BRDT to acetylated chromatin.
Discussion
The BETs are a highly conserved protein family involved in
diverse functions including transcriptional regulation and
chromatin remodelling. Through their bromodomains, they are
known to interact with acetylated histone tails and have a rare
ability to stay associated with chromatin throughout the cell
cycle30–32. Here we have used BRDT as a model for studying the
interactions of the BET bromodomains with acetylated
nucleosomes and ﬁnd that DNA plays a critical role.
BRDT-BD1 interacts with doubly acetylated histone H4 tails
with a low micromolar afﬁnity and associates with chromatin
in vivo in an acetylation-dependent manner16,24. We ﬁnd that
BRDT-BD1 also interacts with DNA and this interaction
stimulates the binding of the bromodomain to acetylated
nucleosomes in vitro and acetylated chromatin in cells. Manual
alignment of a Brdt-BD1-H4K5acK8ac peptide crystal structure
alongside the structure of the nucleosome (1AOI1) suggests how
binding afﬁnity and speciﬁcity may be enhanced (Supplementary
Fig. 11). Orientation of BD1 with its DNA-binding interface
towards the DNA positions the acetyl–lysine-binding pocket in
the correct orientation for interaction with the histone H4 tail.
The distance ofB20Å between H4R17 leaving the surface of the
nucleosome and the pre-aligned BD1 acetyl–lysine pocket would
be bridgeable for the extended histone tail, allowing BD1 to
recognize H4K5acK8ac.
Under this scenario, the non-speciﬁc interaction with DNA
would serve to localize BD1 to nucleosomes and would allow BRDT
to scan chromatin for acetylated histone H4. Stable BD1 binding
would then be dependent on recognition of the appropriate
acetylated lysine residues. BRDT would thus be stabilized on
nucleosomes in a bivalent manner, similar to that of the PWWP
domain of LEDGF, which simultaneously binds H3K36me3 and
DNA to enhance its nucleosome-binding afﬁnity33,34.
A corollary of this model is that the relative position/spacing of
acetylated lysines—relative to the nucleosome core—would
inﬂuence bromodomain target speciﬁcity. We were able to
demonstrate that this is the case by showing that BRDT-BD1
binds to WT and H3-chimeric nucleosomes containing acetyl–
lysine residues in identical sequence contexts, but different
positions, with differing afﬁnities. Thus, the nucleosome structure
imposes an added layer of speciﬁcity to bromodomain binding.
In stark contrast to BRDT-BD1, and predictions on the basis of
peptide-binding studies, we ﬁnd that BD2 neither interacts with
DNA nor with acetylated nucleosomes. Whereas conservation of
the contiguous positively charged patch on the rest of the BET
bromodomains implies conservation of function, BRDT-BD2 has
a considerably more negative electrostatic surface potential
(Fig. 5a). This may actively repel BRDT-BD2 from DNA, thus
preventing an interaction with acetylated histone H3 tails in
the context of the nucleosome, even when BRDT-BD2 is
physically tethered to the nucleosomes by BRDT-BD1 binding
to acetylated H4.
Although nucleosome binding can be enhanced by tandem
domains bivalently binding nucleosomes (2–3-fold enhancement
for bromo-PHD of BPTF35; 3–11-fold enhancement for two PHD
ﬁngers of CHD4 (ref. 36)), this is not the case for BRDT. Unlike
the structured spacer element that connects the PHD and
bromodomain of BPTF35, or the relatively short linker between
the PHD ﬁngers of CHD4 (ref. 36), we ﬁnd that the linker
connecting the bromodomains of BRDT is long (B110 aa) and
disordered (Supplementary Fig. 3). Furthermore, it remains so
upon BRDT binding to nucleosomes (Supplementary Fig. 4b).
With this long ﬂexible linker, the two domains are effectively
independent in solution, precluding any binding enhancement
through ‘prepaying’ entropic costs of positioning the domains for
binding18. Despite this, tethering of BRDT to nucleosomes by
BD1 would still increase the relative local concentration of BD2
and would therefore be expected to increase the likelihood of an
interaction, if it were not inhibited. This has been shown to be the
case for BRD4, where a construct encompassing BRD4-BD1 and
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BD2 was found to bind to nucleosomes acetylated on both
histones H3 and H4 with a 2.6-fold increased afﬁnity over BRD4-
BD1 alone37.
Previous research has shown that BRDT localization and its
ability to compact chromatin in somatic cells are primarily
mediated by BRDT-BD1, while BRDT-BD2 is, at least in part,
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dispensable16,24. Our results give a molecular explanation to the
observed biological data and indicate that BRDT-BD2 may have
an alternate biological function. One possible function, which
would depend on ﬂexible tethering of BD2 to nucleosomes by
BD1, would be the recruitment of an acetylated non-histone
protein to chromatin. BRDT would not be unique in this
function; other BET proteins are also known to use their
bromodomains for interactions with acetylated non-histone
proteins38–42.
Possible candidates for BRDT-BD2 recruitment would be the
transition proteins (TPs) and protamines (Prms); both of which
are known to be acetylated43–45, and both of which are critical for
BRDT-mediated post-meiotic genome repackaging during
spermatogenesis12. TPs and Prms depend on BRDT for nuclear
localization in elongating spermatids, and loss of BD1 leads to
their accumulation in the cytoplasm, preventing histone
replacement12. Although BRDT has a nuclear localization
sequence, this data indicates that chromatin binding by BRDT-
BD1 is required for nuclear retention of BRDT, TPs and Prms
and therefore that BRDT interacts, either directly, or indirectly,
with TPs and Prms—potentially via BRDT-BD2.
In contrast to BRDT-BD1 and BD2, BRD4-BD1 has unam-
biguously been shown to bind to histone peptides14,31,
mononucleosomes37 and chromatin31, but also to other non-
histone acetylated proteins (reviewed in ref. 5). We ﬁnd that
BRD4-BD1 does not interact with DNA, which led us to compare
BRD4-BD1 and BRDT-BD1 binding to acetylated nucleosomes
by ITC. Although BRDT-BD1 and BRD4-BD1 have similar
binding afﬁnities for H4K5acK8ac peptides, their binding afﬁnities
for nucleosomes differed signiﬁcantly (B6-fold). This is largely
because BRD4-BD1 does not show any enhancement of binding
afﬁnity for nucleosomes over isolated peptides.
On the basis of our data, we propose three models for how BET
bromodomains interact with nucleosomes (Fig. 7). BRDT-BD1
has a non-speciﬁc DNA-binding activity, which allows position-
ing of the bromodomain on the nucleosome for interaction with
acetylated histone H4 tails. This bivalent interaction thus
enhances the binding afﬁnity and speciﬁcity of BRDT-BD1 for
nucleosomes (Fig. 7a). BRDT-BD2 does not interact with DNA or
nucleosomes (Fig. 7a), likely due to electrostatic repulsion from
the DNA preventing BRDT-BD2 from accessing the histone H3
tail. Thus, it cannot enhance the binding of BRDT to
nucleosomes. Finally, BRD4-BD1 retains a positively charged
interface on a polarized surface but does not interact with DNA
with an afﬁnity measurable in our experiments. This domain
interacts with H4K5acK8ac, however, it shows no enhancement of
binding stimulated by the nucleosome context. Unlike BRDT,
BRD4 binding to nucleosomes is enhanced by simultaneous
binding of both of its bromodomains37 (Fig. 7b).
Like BRD4-BD1, we show that BRD3-BD1 does not interact
with DNA, while BRD2-BD1, BRD2-BD2, BRD3-BD2 and
BRD4-BD2 do. In future work it will be interesting to assess
the importance of these ﬁndings in nucleosome binding,
transcriptional regulation and chromatin remodelling by the
BET proteins in vivo. Furthermore, the BET bromodomains are
just 8 of 61 human bromodomains. Our work provides a
demonstration of DNA binding by a member of the bromodo-
main family; it will be intriguing to see whether bivalent binding
of DNA and acetylated histone tails by bromodomains is a
conserved feature of the wider bromodomain family of chromatin
‘reader’ modules.
In summary, we have used BRDT as a model to study the
binding of BET bromodomains to site-speciﬁcally acetylated
nucleosomes. ITC experiments revealed that BRDT-BD1 has an
enhanced afﬁnity for acetylated nucleosomes over acetylated
histone peptides, whereas BRDT-BD2 does not interact with
acetylated nucleosomes, in contrast to predictions on the basis of
peptide-binding studies. Using a range of biophysical methods
and mutational analyses, both in vitro and in cells, we show that
BRDT-BD1 bivalently interacts with acetylated nucleosomes and
chromatin through concomitant interaction with histone H4 and
DNA. We show that bromodomain-mediated DNA binding is
conserved among members of the BET family, indicating that
bivalent nucleosome recognition through simultaneous DNA and
histone tail binding is an important component of nucleosome
recognition by BET bromodomains and possibly in bromodo-
mains beyond the BET family. Our results emphasize the
importance of studying chromatin reader’s interactions with
nucleosomes rather than isolated peptides or DNA. Accordingly,
this study provides important insight into the molecular
mechanism of BET association with chromatin and shows that
features outside of the bromodomains’ histone-binding pockets
are crucial for interactions with nucleosomes. Knowledge of these
features may pave the way for enhanced targeting of speciﬁc BET
bromodomains for therapeutic purposes.
Methods
Expression and puriﬁcation of human BET constructs. BRDT constructs
N-BRDT(1) (aas 1–143), BRDT(2) (aas 258–383) and BRDT(1–2) (aas 1–383) were
cloned using restriction-free cloning46 as N-terminally His-TEV-tagged fusion
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Figure 7 | Schematic models of BRDT and BRD4 bromodomains interacting with acetylated nucleosomes. (a) BRDT interacts with acetylated
nucleosomes via its BD1 domain. Binding may be initiated through non-speciﬁc interactions with DNA, which allow BRDT to localize to chromatin.
Speciﬁcity is generated through recognition of tandem acetylated lysine residues (K5ac/K8ac) on the histone H4 tail, while the afﬁnity of the interaction is
enhanced by bivalent interaction with both the histone tail and DNA. In contrast, BRDT-BD2 does not interact with acetylated nucleosomes and therefore is
ﬂexibly tethered to nucleosomes via BRDT-BD1. BRDT-BD2 may function to recruit as-yet-unknown acetylated non-histone proteins to the chromatin.
(b) BRD4 interacts with acetylated nucleosomes via both its BD1 and BD2 domains. Our results indicate that BRD4-BD1 binds to nucleosomes through the
acetylated histone H4 tail and does not additionally interact with DNA. Bivalent binding of BRD4 through both bromodomains has previously been shown
to enhance BRD4 binding afﬁnity for nucleosomes by 2.6-fold37.
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proteins into pETM11 expression vectors. Original sequences were ampliﬁed from
cDNA clones provided by Sino Biological Inc (catalogue number: HG11602-M).
BET bromodomains BRD2(2) (aas 348–455), BRD3(1) (aas 24–144), BRD3(2)
(aas 306–416), BRD4(1) (aas 44–168) and BRD4(2) (aas 333–460) were gifts
from Nicola Burgess-Brown provided through Addgene (plasmid numbers: 53626,
38940, 38941, 38942 and 38943, respectively). Codon-optimized BRD2(1)
(aas 48–184; Euroﬁns) was cloned using restriction-free cloning46 as an
N-terminally His-TEV-tagged fusion protein into the pETM11 expression vector.
Plasmids were transformed into the Escherichia coli strain BL21-CodonPlus
(DE3)-RIL (Stratagene), and the bacteria were grown in Luria-Bertani
(LB) medium supplemented with 50 mgml 1 kanamycin and 25mgml 1
chloramphenicol at 37 C. Expression of recombinant proteins was induced by
addition of 0.4 mM IPTG at an OD600 of 0.6 followed by overnight incubation at
18 C. The bacterial cell pellets were resuspended in lysis buffer (50mM Tris
(pH 8.0), 500mM NaCl, Complete EDTA-free Protease Inhibitor Cocktail (Roche),
DNase1 (Roche), 0.25mM DTT) before being lysed by sonication and clariﬁed by
centrifugation at 75,600g. Proteins were puriﬁed from the soluble fraction using
nickel-NTA agarose (Qiagen), followed by TEV protease cleavage of the
N-terminal His-tag and additional puriﬁcation over Ni-NTA resin to remove the
tags and His-tagged TEV protease. Finally, proteins were further puriﬁed by size
exclusion chromatography using Superdex 75 or 200 columns (GE Healthcare)
as appropriate. The purity and structural integrity of the puriﬁed proteins was
monitored by SDS–PAGE and 1H NMR (Supplementary Fig. 12).
NMR labelled BRDT constructs. For NMR experiments, labelled proteins were
obtained by expression in M9 media (containing 100% D2O for uniformly deut-
erated proteins); 13C and 15N labelling was achieved through the addition of 13C
glucose (4 g l 1) and 15NH4Cl (1 g l 1), while speciﬁc 13C, 1H labelling of ILV-
methyl groups was achieved through the addition of sodium salts of labelled alpha-
ketoisovaleric acid (1,2,3,4-13C4; 3,4’,4’,4’-D4 for N-BRDT(1); 3-methyl-13C;
3,4,4,4-D4 for BRDT(2) and BRDT(1–2); 120mg l 1) and alpha-ketobutyric acid
(13C4; 3,3-D2 for N-BRDT(1); methyl-13C; 3,3-D2 for BRDT(2) and BRDT(1–2);
60mg l 1) when the cells reached an OD600 of 0.6. Protein expression was induced
by IPTG (0.4mM) and carried out overnight at 18 C. This protocol was on the
basis of the protocol developed by the Kay laboratory47. NMR isotopes were
obtained from Cambridge Isotope Laboratories. Proteins were puriﬁed as described
for the unlabelled equivalents, with a ﬁnal dialysis step into NMR buffer
(25mM sodium phosphate (pH 6.7), 100mM NaCl) prepared with H2O or D2O as
appropriate.
Nucleosome preparation. Full-length unmodiﬁed histones. Histones H2A/H2B–
Codon-optimized (supplied by Entelechon – now Euroﬁns), full-length human
histones H2A/H2B were co-expressed from a pCDF-DUET vector transformed
into the E. coli strain BL21-CodonPlus (DE3)-RIL (Stratagene). Bacteria were
grown in LB medium supplemented with 100mgml 1 streptomycin and
25mgml 1 chloramphenicol at 37 C and induced at an OD600of 0.6 with IPTG
(0.25mM). Cells were collected after 4 h by centrifugation. Cell pellets were
resuspended in cold lysis buffer (20mM Tris (pH 8.0), 100mM NaCl, 0.1mM
EDTA, 10mM b-mercaptoethanol and Complete EDTA-free Protease Inhibitor
Cocktail (Roche)) and the cells lysed using an Emulsiﬂex-C3 homogenizer
(Avestin) and clariﬁed by centrifugation at 75,600g. Clariﬁed cell lysate was ﬁltered
using a 0.45 mm syringe ﬁlter (Merck Millipore) and injected onto combined 5ml
HiTrap Q HP and HiTrap Heparin HP columns (GE Healthcare) pre-equilibrated
in lysis buffer. Columns were washed with one column volume of lysis buffer
before detaching the HiTrap Q HP column. The HiTrap Heparin HP column was
subsequently washed with 20% elution buffer (20mM Tris (pH 8.0), 2M NaCl,
0.1mM EDTA, 10mM b-mercaptoethanol) before eluting the H2A/H2B complex
with a 20CV gradient into 100% elution buffer. The pooled and concentrated
fractions containing the H2A/H2B dimer were further puriﬁed by size exclusion
chromatography over a Superdex 75 column (GE Healthcare). Protein purity was
monitored by SDS–PAGE. The H2A/H2B complex was extensively dialysed into
1mM DTT before lyophilisation and storage at  80 C.
Histones H3 and H4 – Codon-optimized (supplied by Entelechon – now
Euroﬁns), full-length human histone H3 and histone H4 (kindly provided by
T.Bartke) were individually expressed from pETM-13 and pETM-21b(þ ) vectors
transformed into the E. coli strain Rosetta (DE3) pLysS (Novagen). Bacteria were
grown in LB medium supplemented with 50 mgml 1 kanamycin (H3) or
ampicillin (H4) and 25mgml 1 chloramphenicol at 37 C and induced at an
OD600 of 0.6 with IPTG (0.25mM). Cells were collected after 4 h by centrifugation.
Histones were puriﬁed essentially as previously described48. Cell pellets were
resuspended in cold histone wash buffer (50mM Tris (pH 7.5), 100mM NaCl,
1mM EDTA and Complete EDTA-free Protease Inhibitor Cocktail (Roche)). Cells
were lysed using an Emulsiﬂex-C3 homogenizer (Avestin) and inclusion bodies
pelleted by centrifugation at 12,000g. Pellets were resuspended in cold histone wash
buffer þ 1% Triton-X-100 in a Dounce homogenizer and inclusion bodies again
pelleted by centrifugation at 12,000g. Inclusion body washing was repeated twice
with Triton-X-100, before two ﬁnal washes into histone wash buffer. Inclusion
bodies were resuspended in unfolding buffer (20mM Tris (pH 7.5), 7M guanidine
hydrochloride and 100mM DTT) for 1 h at room temperature, before clariﬁcation
by centrifugation at 20,000g. Supernatants were ﬁltered using a 0.45 mm syringe
ﬁlter (Merck Millipore) and histones puriﬁed by size exclusion chromatography
over a Superdex 200 column (GE Healthcare) in SAU-1000 buffer (7M urea,
20mM sodium acetate (pH 5.2), 1M NaCl, 1mM EDTA and 5mM
b-mercaptoethanol). Fractions containing histone H3 or H4 were pooled and
diluted to bring the NaCl concentration to below 200mM and loaded on to a
HiTrap SP HP column (GE Healthcare) equilibrated in SAU-200 (as above, with
200mM NaCl). Histone H3 was eluted using a gradient into SAU-600 buffer
(as above, with 600mM NaCl). Histone H4 was eluted using a gradient into
TU-1000 buffer (7M urea, 20mM Tris (pH 7.5), 1M NaCl, 1mM EDTA and
5mM b-mercaptoethanol). Protein purity was monitored by SDS–PAGE. The H3
and H4 histones were extensively dialysed into 1mM DTT before lyophilisation
and storage at  80 C.
Truncated histones H3 and H4 for native chemical ligation. Codon-optimized
human histones H3 and H4 (supplied by Entelechon – now Euroﬁns) were used for
cloning H3(A25C) and H4(A15C) mutants into a pETM13 vector using restric-
tion-free cloning46. These constructs contain an N-terminal methionine initiation
codon immediately followed by the alanine-to-cysteine mutation, thus lack residues
2–24 and 2–14, respectively. The E. coli methionyl-aminopeptidase removes the
N-terminal methionine thus exposing the cysteine at the N-terminus. Plasmids
were transformed into the E. coli strain Rosetta (DE3) pLysS (Novagen), and
bacteria were grown in LB medium supplemented with 50 mgml 1 kanamycin and
25 mgml 1 chloramphenicol at 37 C. Cells were induced at an OD600of 0.6 with
IPTG (0.25mM) and collected after 4 h by centrifugation. The truncated histones
were puriﬁed as described for full-length H3 but in the absence of reducing agents.
Puriﬁed histones were dialysed into water and lyophilized.
Native chemical ligation. For ligations, truncated histones H3(A25C) and
H4(A15C) were incubated with acetylated histone peptides carrying a C-terminal
thioester in ligation buffer (200mM NaPO4 (pH 7.5), 0.5mM TCEP, 6M guani-
dine HCl, 100mM sodium 2-mercaptoethanesulfonate) for 24 h at 25 C. The
reactions were stopped by adding DTT to a ﬁnal concentration of 100mM.
Ligated H3 was diluted in SAU-0 (7M urea, 20mM sodium acetate (pH 5.2),
1mM EDTA, 5mM b-mercaptoethanol) to dilute the guanidine HCl concentration
to o200mM and the protein was loaded on to a HiTrap SP HP column
(GE Healthcare) pre-equilibrated in SAU-200 (200mM NaCl). A 5 CV gradient to
25% SAU-600 (600mM NaCl) followed by 10 CV at 25% eluted the vast majority
of unligated H3. Ligated H3 was eluted with a 5 CV gradient to 50% SAU-600
followed by a step to 100% SAU-600 to remove any remaining protein. Protein
purity was checked by 18% SDS–PAGE and impure fractions were pooled for a
second round of puriﬁcation.
Truncated H4(A15C) and H3(A25C) (for chimeric nucleosomes) were ligated
to a peptide consisting of a His-tag, TEV-cleavage site and the H4 N-terminal
sequence (1–14) and therefore could be puriﬁed using Ni-NTA agarose (Qiagen).
Ligated H4 was extensively dialysed into binding buffer (100mM NaPO4,
10mM Tris, 6M guanidine HCl, pH adjusted to 8.0) and then incubated with
pre-equilibrated Ni-NTA resin. Ligated H4 was eluted with elution buffer
(100mM NaPO4, 10mM Tris, 8M urea, pH adjusted to 4.5) and dialysed into
1mM DTT before lyophilisation. Protein purity was checked by 18% SDS–PAGE.
167 bp Widom DNA. A plasmid containing 80 repeats of 167 bp with a centered
Widom 601 sequence49 was ampliﬁed in XL1 Blue cells (Stratagene). Plasmid DNA
was puriﬁed by Gigaprep (Qiagen) using the standard protocol. Puriﬁed plasmid
was digested using AvaI (NEB) to isolate 167 bp repeats, which were puriﬁed from
the vector backbone by size exclusion chromatography with an XK 16/70 Superose
6 pg (GE Healthcare) gel ﬁltration column. Puriﬁed DNA was precipitated by
addition of 0.7 volumes of isopropanol and 0.3M sodium acetate and pelleted by
centrifugation at 20,000g for 1 h at 4 C. DNA was resuspended in TE buffer
(10mM Tris (pH 8.0), 1mM EDTA) and the purity checked on a 2% agarose gel.
Nucleosome reconstitution. Histone octamers were refolded from puriﬁed
histones and assembled into nucleosomes with 167 bp DNA by salt deposition48.
Histone aliquots were dissolved in unfolding buffer (20mM Tris (pH 7.5),
6M guanidine hydrochloride and 20mM DTT), before being mixed in equimolar
ratios and diluted to give a ﬁnal protein concentration of 1mgml 1. The histones
were then dialysed at 4 C against refolding buffer (10mM Tris (pH 7.5), 2M NaCl,
1mM EDTA and 5mM b-mercaptoethanol). Refolded octamers were concentrated
and then puriﬁed by size exclusion chromatography over a Superdex 200 column
(GE Healthcare). Puriﬁed histone octamers were mixed with 167 bp Widom DNA
in refolding buffer and diluted to a ﬁnal DNA concentration of 0.7mgml 1. The
samples were dialysed into buffers containing 20mM Tris (pH 7.5) 5mM
b-mercaptoethanol and 1mM EDTA, with decreasing concentrations of NaCl
(2M, 850mM, 650mM and 150mM). Reconstitution conditions were optimized
by titration and nucleosomes checked by 5% native PAGE. N-terminal His-tags on
ligated H4 of H4K5K8ac nucleosomes and H3-H4K5acK8ac chimeric nucleosomes
were removed by TEV cleavage (2 h, 30 C) of reconstituted nucleosomes
(Supplementary Fig. 1). Cleaved nucleosomes were puriﬁed by incubation with
Ni-NTA agarose and collection of ﬂow-through. Chimeric nucleosomes contained
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chimeric H3-H4K5acK8ac and WT H2A, H2B and H4, and thus contained both
modiﬁed and unmodiﬁed H4 tail sequences.
Isothermal titration calorimetry. ITC was carried out at 20 C with an ITC
200 Microcalorimeter (GE Healthcare) following dialysis of puriﬁed BRDT
proteins and nucleosomes into interaction buffer (20mM Tris (pH 8.0), 150mM
NaCl, 1mM EDTA and 1mM TCEP). For BRDT and BRD4 BD1 peptide-binding
experiments, histone peptides (450 mM) were titrated into BD1 proteins
(25–30 mM). For BRDT-BD2 peptide-binding experiments, histone peptides
(2.5mM) were titrated into BRDT-BD2 proteins (90 mM). For nucleosome-binding
experiments, BET bromodomain proteins (200–260 mM) were titrated into
nucleosomes (6–11 mM). Peptides were supplied by Peptide Protein Research Ltd
and were solubilized in interaction buffer. ITC data was analyzed with using the
MicroCal Origin software package after correction for heats of dilution.
A summary of all ITC presented in this paper can be found in Supplementary
Table 1.
Nuclear magnetic resonance. NMR experiments were performed on Bruker
Avance III 600 and 800MHz spectrometers equipped with HCN triple-resonance
cryo-probes. Protein assignments were obtained using a combination of standard
triple resonance experiments50. Nucleosome interaction was monitored by 13C-1H
HMQC experiments recorded for 20 h on labelled BRDT constructs titrated into
acetylated histones or nucleosomes (10 mM) at 34 C. NMR data were processed by
NMRPipe51 and analyzed with NMRView52.
Electrophoretic mobility shift assays. For the binding reaction, a master mix
containing DNA and reaction buffer (20mM Tris (pH 7.5), 100mM NaCl, 5mM
DTT, 0.5mM EDTA) was prepared and mixed with dilutions of BRDT constructs
to the ﬁnal concentrations indicated. Binding was performed for 30min at 4 C.
BRDT-DNA complexes were resolved by PAGE (5–7% polyacrylamide, 3%
glycerol and 0.5 TAE) at 100V for B1.5 h (4 C). Experiments utilizing 167 bp
DNA were stained with ethidium bromide and imaged using the AlphaImager HP
imaging system (Proteinsimple). EMSA gels using 32P-labelled 25 and 66 bp
dsDNA oligos were dried and exposed to a phosphorimager screen. Unbound
DNA was quantiﬁed as a proportion of total signal/lane using a Typhoon imager
with ImageQuant software and data plotted against protein concentration to
calculate the binding afﬁnities indicated.
DNA sequences used for EMSA-binding studies. 167bp Widom DNA.
Forward—50-tcgggggccgccctggagaatcccggtgccgaggccgctcaattggtcgtagacagctctagcac
cgcttaaacgcacgtacgc-30 50-gctgtcccccgcgttttaaccgccaaggggattactccctagtctccaggcacgt
gtcagatatatacatcctgtgcatgtac-30
Reverse—50-ccgagtacatgcacaggatgtatatatctgacacgtgcctggagactagggagtaatccccttgg
cggttaaaacgcgggggacagc-30 50-gcgtacgtgcgtttaagcggtgctagagctgtctacgaccaattgagcggcc
tcggcaccgggattctccagggcggccc-30
66 bp DNA. 50-cgatatagtgtaacggctatcacatcacgctttcaccgtggagaccggggttcgact
ccccgtatc-30
25 bp DNA. 50-cgaagtggccgagtggtctatggcg-30 .
Fluorescence recovery after photobleaching. FRAP experiments were
performed as previously described16. In brief, 1.5 mg of each of the GFP-BRDT
constructs was transfected into Cos7 cells using lipofectamine 2000. Cells were
treated with TSA (50 ngml 1) and incubated at 37 C in 5% CO2 for 16 h.
FRAP analysis was performed using a Zeiss microscope (LSM710 NLO-LIVE7-
Confocor3) equipped with a 488 nm laser and a LP505 ﬁlter, on 10 independent
cells. A circular region was bleached for 1.22 s; ﬂuorescence recovery curves
were individually ﬁtted with the ZEN software using the single exponential model
I tð Þ ¼ Að1 e tT1 Þ, where I tð Þ represents the ﬂuorescence intensity as a function
of time t and A is the mean post-bleached ﬂuorescence signal. Recovery times (t1/2)
were determined using t1/2¼T1ln(2) for each dataset individually and used to
calculate the mean. Cos7 cells (ATCC CRL1651) were authenticated and supplied
by the American Type Culture Collection (ATCC). This cell line has been tested
for mycoplasma contamination with the MycoAlert Mycoplasma Detection Kit
(Lonza).
Analytical ultracentrifugation. Analytical centrifugation was perform in a
Beckman Optima XL-A centrifuge ﬁtted with AN-60 rotor and double-sector
aluminum centerpieces (40,000 r.p.m.; 129,000g; 4 C). Sedimentation velocity
proﬁles were recorded at 280 nm. Molecular weight distributions were determined
by the C(s) method implemented in the Sedﬁt software53.
Small angle X-ray scattering. SAXS data of BRDT(1-2) were acquired at BM29 at
the ESRF54, Grenoble with protein concentrations of 0.5, 1, 2 and 4mgml 1 in a
buffer containing 25mM tris (pH 8) and 200mM NaCl supplemented with 2mM
dithiothreitol (DTT) to reduce radiation damage. Measurements were carried out
at 20 C with samples exposed for 10 frames of 1 s each at full transmission. The
data were analyzed with the ATSAS package55. The ﬁnal curve was generated by
extrapolating the data to zero concentration.
Data availability. All relevant data reported in this paper are available from the
authors upon reasonable request. The following PDB structures were used in this
study: human BET bromodomains BRDT-BD1 (2RFJ), BRD3-BD1 (2NXB),
BRD3-BD2 (2OO1), BRD4-BD1 (2OSS), BRD4-BD2 (2OUO), BRD2-BD1 (1X0J)
and BRD2-BD2 (2DVV).
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